Cardiovascular Risk of Non-Opioid Pain Medications
非阿片类止痛药的心血管风险
基本信息
- 批准号:10041689
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcetaminophenAddressAdrenergic AgentsAdverse drug effectAdverse effectsAmericanAmitriptylineAnalgesicsAnti-Inflammatory AgentsAnticonvulsantsAntidepressive AgentsAntiepileptic AgentsArrhythmiaAttentionAwarenessBindingBlood PressureCalciumCalcium ChannelCardiomyopathiesCardiotoxicityCardiovascular DiseasesCardiovascular systemCaringCase StudyCatecholaminesCessation of lifeChronicClinical TrialsComplexCongestive Heart FailureDataDatabasesDrug ControlsDrug PrescriptionsDrug ProspectingDrug Side EffectsDrug toxicityDrug usageEuropeanEventExerciseFaceFibromyalgiaGeneral PopulationGoalsGovernment AgenciesGuidelinesHealthHealth systemHeart ArrestHeart RateHeart failureHigh PrevalenceHypotensionInotropismKnowledgeLidocaineLifeLiquid substanceLong-Term EffectsLongitudinal StudiesMalignant NeoplasmsManufacturer NameMedicalMedical AssistanceMedicineMethodsMissionMuscle relaxantsMyocardial InfarctionNorepinephrineOpioidOpioid AnalgesicsOralOutcomeOutcome StudyOverdosePainPain managementPatientsPharmaceutical PreparationsPharmacoepidemiologyPharmacologyPlayPopulationRecording of previous eventsReportingResearchResearch PersonnelRetrospective cohort studyRiskRoleSafetySeriesSerotoninStress cardiomyopathyStructureSystemTachycardiaTechniquesTestingTimeToxic effectTramadolTreatment EfficacyUnited StatesUnited States Department of Veterans AffairsUnited States Food and Drug AdministrationVeteransVeterans Health AdministrationVulnerable Populationsactive comparatoractive controlattenuationcardiovascular risk factorcelecoxibchronic painchronic pain managementchronic pain patientcohortdesigndrug mechanismduloxetineepidemiology studyexperiencehigh dimensionalityhigh riskimprovedinhibitor/antagonistmedication safetymidalcipranmilitary veterannon-cancer chronic painnon-opioid analgesicnovelpregabalinpreventreuptakeside effectstudy populationvoltage
项目摘要
PROJECT SUMMARY
When compared to the general population, U.S. Military Veterans disproportionately experience pain, especially
severe pain. Indeed, pain management is one of the most common reasons Veterans seek medical assistance.
The U.S. Department of Veterans Affairs (VA) and Veterans Health Administration (VHA) have continued to
focus attention on chronic pain management, which has resulted in the implementation of new guidelines and
systems that prioritize non-opioid treatments.
Current pharmacologic alternatives to opioids for chronic pain management include: (1) topical and oral
analgesics such as lidocaine, acetaminophen, and non-steroidal anti-inflammatories (NSAIDs); (2)
antidepressants; (3) anticonvulsants; and (4) muscle relaxants. We and others have defined the cardiovascular
toxicity of NSAIDs and opioid analgesics, but the potential toxicity of other drug classes used to treat chronic
pain remains poorly defined. This is particularly important for three classes of drugs: (1) selective norepinephrine
reuptake inhibitors (SNRIs) antidepressants, (2) antiepileptics, and (3) muscle relaxants. Within each drug class,
duloxetine (SNRI), pregabalin (antiepileptic), and cyclobenzaprine (muscle relaxant) are among the most
frequently prescribed. Usage of these three drugs has generated multiple case reports and raised specific
concerns for increased risk of serious cardiovascular events.
Currently, hundreds of thousands of Veterans are filling prescriptions for these drugs each year, and the use of
non-opioid pain drugs is increasing. Veterans encompass a vulnerable population with high cardiovascular risk
and high rates of chronic pain; thus, they are at higher risk for adverse drug effects. The overwhelming majority
of Veterans with chronic pain do not have cancer or life-threatening illness, which makes the prospect of drug
toxicity from long-term use a particularly important consideration.
Clinical trials play a crucial role in demonstrating treatments' efficacy; however, many drugs have had unforeseen
and serious side effects. Since clinical trials necessarily are limited with regard to generalizability and can be
impractical, pharmacoepidemiologic studies play a critical role in our knowledge about the long-term side effects
of drugs. The proposed pharmacoepidemiologic studies seek to provide critical information about the
cardiovascular risks associated with three widely prescribed non-opioid medications used to treat chronic pain
and frequently prescribed to Veterans in the VA health system. We will use state of the art techniques and a
large database of Veterans to assemble a cohort of patients with chronic non-cancer pain. Aim 1 will define the
risk for serious cardiovascular outcomes in patients taking cyclobenzaprine. Aim 2 will define the risk of serious
cardiovascular events associated with the use of duloxetine. Aim 3 will define the risk of heart failure associated
in patients taking pregabalin. These studies will compare those risks with the risk observed in patients with
chronic pain taking two active comparators: tramadol and celecoxib. Our overarching goal to improve the health
of Veterans and prevent negative side effects makes these studies an excellent fit with the VA mission.
项目摘要
与一般人群相比,美国退伍军人不成比例地经历疼痛,特别是
剧烈的疼痛。事实上,疼痛管理是退伍军人寻求医疗援助的最常见原因之一。
美国退伍军人事务部(VA)和退伍军人健康管理局(VHA)继续
将注意力集中在慢性疼痛管理上,这导致了新指南的实施,
优先考虑非阿片类药物治疗的系统。
目前阿片类药物治疗慢性疼痛的替代药物包括:(1)局部和口服
镇痛药,如利多卡因、对乙酰氨基酚和非甾体抗炎药(NSAID);(2)
抗抑郁药;(3)抗惊厥药;和(4)肌肉松弛药。我们和其他人已经定义了心血管
NSAID和阿片类镇痛药的毒性,但用于治疗慢性
疼痛的定义仍然不明确。这对三类药物尤为重要:(1)选择性去甲肾上腺素
再摄取抑制剂(SNRIs)抗抑郁药,(2)抗癫痫药,和(3)肌肉松弛药。在每一类毒品中,
度洛沙汀(SNRI)、普瑞巴林(抗癫痫药)和环苯扎林(肌肉松弛剂)是最常用的药物之一。
经常开处方。这三种药物的使用产生了多个病例报告,并提出了具体的
严重心血管事件风险增加的担忧。
目前,每年有数十万退伍军人正在填写这些药物的处方,
非阿片类止痛药的使用正在增加。退伍军人包括具有高心血管风险的脆弱人群
和慢性疼痛的高比率;因此,他们有更高的药物不良反应的风险。绝大多数
的慢性疼痛退伍军人没有癌症或危及生命的疾病,这使得药物的前景
长期使用的毒性是特别重要的考虑因素。
临床试验在证明治疗效果方面发挥着至关重要的作用;然而,许多药物都有不可预见的
和严重的副作用由于临床试验在普遍性方面必然是有限的,
不切实际的药物流行病学研究在我们对长期副作用的认识中起着关键作用,
毒品拟定的药物流行病学研究旨在提供关于
与三种广泛用于治疗慢性疼痛的非阿片类药物相关的心血管风险
并经常开给退伍军人管理局卫生系统的退伍军人。我们将使用最先进的技术和
一个大型的退伍军人数据库,以收集一组慢性非癌症疼痛患者。目标1将定义
服用环苯扎林患者发生严重心血管事件的风险目标2将定义严重风险
与使用度洛昔单抗相关的心血管事件。目标3将定义心力衰竭相关风险
服用普瑞巴林的患者这些研究将比较这些风险与患者中观察到的风险,
慢性疼痛,服用两种活性对照药物:曲马多和塞来昔布。我们的首要目标是改善
退伍军人和防止负面副作用,使这些研究非常适合与退伍军人事务部使命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cecilia Pilar Chung其他文献
Cecilia Pilar Chung的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cecilia Pilar Chung', 18)}}的其他基金
A Personalized Medicine Approach to Improve the Prediction of Azathioprine Toxicity
改善硫唑嘌呤毒性预测的个性化医疗方法
- 批准号:
10225430 - 财政年份:2018
- 资助金额:
-- - 项目类别:
A Personalized Medicine Approach to Improve the Prediction of Azathioprine Toxicity
改善硫唑嘌呤毒性预测的个性化医疗方法
- 批准号:
10453718 - 财政年份:2018
- 资助金额:
-- - 项目类别:
A Personalized Medicine Approach to Improve the Prediction of Azathioprine Toxicity
改善硫唑嘌呤毒性预测的个性化医疗方法
- 批准号:
10783440 - 财政年份:2018
- 资助金额:
-- - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant